Halozyme Therapeutics Inc. HALO) on Tuesday reported second-quarter net income of $165.2 million. On a per-share basis, the ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2025, provided an update on its recent ...

Halozyme Therapeutics (NASDAQ:HALO) reported non-GAAP earnings per share (EPS) of $1.54, beating non-GAAP estimates by $0.30 and growing 69% year over year (non-GAAP). Revenue (GAAP) was $325.7 ...

Analysts expect Halozyme Therapeutics to report an earnings per share (EPS) of $1.20. Anticipation surrounds Halozyme ...

The company raised its full-year 2025 guidance, now expecting earnings per share of $6.00-$6.40, well above the consensus estimate of $5.40. Halozyme also increased its revenue forecast to $1.27-1.35 ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $0.91 per share a year ago.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The ...

Review the current valuation for Halozyme Therapeutics Inc (HALO:XNAS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Review the current Halozyme Therapeutics Inc (HALO:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if HALO is the best investment for you.

The SPDR® S&P Biotech ETF rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a ...